We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Rocket Pharmaceuticals reported that its trial of a gene therapy targeted toward an aggressive and fatal rare disease in children had a 100 percent survival rate at one year — and the company expects to file for regulatory approval of the treatment in the first half of 2023. Read More
In a new draft guidance, the FDA presses drug manufacturers to develop risk management plans to further shore up the country’s drug supply chain. Read More
The European Medicines Agency’s (EMA) human medicines committee endorsed nine new drugs during its monthly meeting held from May 16 to 19, including LFB Biotechnologies’ coagulant therapy Cevenfacta (eptacog beta (activated)) for treating congenital hemophilia. Read More
Sens. Chuck Grassley (R-Iowa), Ron Wyden (D-Ore.) and Mike Braun (R-Ind.) are urging the Federal Trade Commission (FTC) to examine how pharmacy benefit managers (PBM) affect the cost of insulin products. Read More
Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, plus additional payments for reaching developmental or regulatory milestones. Read More
A collection of 24 states is displaying its support to the Department of Health and Human Services (HHS) in its legal fight with several drugmakers over access to drugs discounted under the 340B Drug Discount program. Read More
The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices voted yesterday to recommend that children between the ages of five and 11 should receive booster doses of the Pfizer-BioNTech COVID-19 vaccine. Read More
FDA Commissioner Robert Califf announced a new role for agency veteran Janet Woodcock in his remarks at a House subcommittee hearing yesterday, where he was slated to speak on the agency’s fiscal 2023 budget request. Read More
In a congressionally mandated report on diversity in clinical trials, the National Academies of Sciences, Engineering and Medicine (NASEM) recommends the FDA require drug sponsors to file an in-depth recruitment strategy, either before or with their investigational new drug (IND) or investigational device exemption (IDE) applications, that details how they intend to make their trial population reflective of the disease or condition’s demographics. Read More